21 results about "Neurodegeneration" patented technology

Disclosed in the present application are a method and drug for preventing or treating a neurodegenerative disease, whereby a therapeutically effective amount of gliclazide or a pharmaceutically acceptable salt thereof or a combination of gliclazide or a pharmaceutically acceptable salt thereof and acetaminophen or a pharmaceutically acceptable salt thereof is used or comprised. The method and drug of the present invention can significantly alleviate symptoms such as hyposmia, cognitive dysfunction, and psychiatric symptoms in patients with neurodegenerative diseases that cannot be treated with existing drugs, and can be particularly used for controlling the progression of neurodegenerative diseases.

The invention relates to gene therapy, and more specifically, to AAV gene therapy vectors containing a novel chimeric deoxyribonuclease (DNase) protein transgene and methods of treating ailments such as cancer and neurodegeneration.

The invention relates to an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential for use in the treatment of Alzheimer's and certain neurodegenerative disorders.

Methods and composition are provided for treatment of various disorders associated with decreased neurogenesis, including age-related neurodegeneration, such as Alzheimer' s disease.

Provided are compounds having the following structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X 1 , X 2 , Q, R 1 , R 2 , and n are as defined herein. Such compounds are useful as thyromimetic agents and have utility for treating diseases such as neurodegenerative diseases and fibrotic diseases. Also provided are pharmaceutical compositions containing such compounds, as well as methods of their use and preparation.

The present invention relates to a DHP-I inhibitor for use in a method for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease. In some embodiments, it relates to a DHP-I inhibitor for use in a method for the prophylactic treatment of neurodegeneration. The present invention also relates to a DHP-I inhibitor for use as neuroprotectant. It further pertains to related methods for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease and the use of a DHP-I inhibitor in the manufacturing of a medicament for use in these methods. The present invention also provides pharmaceutical compositions and delivery systems for use in the methods of the invention, as well as to a pharmaceutical composition or drug delivery systems suitable for administration by a route bypassing the blood brain barrier (BBB) and / or the blood retinal barrier (BRB), preferably selected intrathecal, intracranial, intranasal and / or ocular administration; or suitable for trespassing the BBB and / or the BRB.

Methods and compositions for manipulating metabolism in astrocytes to improve astrocytic and neuronal function, as well as individual pathology hallmarks and symptoms during the development of neurodegeneration by increasing PPARα expression and activity specifically in astrocytes within the central nervous system to treat a variety of neurodegenerative conditions including but not limited to conditions involving neuronal lipid dysregulation, oxidative damage, accumulation of β-amyloid or other protein aggregates, dementia, and motor dysfunction. Also provided are methods of treating peripheral metabolic dysfunction associated with neurodegenerative conditions.

To provide pharmaceutical compositions for the diagnosis, prevention, and / or treatment of age-related cognitive decline, including pathological neurodegeneration. [Solution] A pharmaceutical composition comprising the following components: a therapeutically effective amount of one or more of the following: a CD103 inhibitor, a perforin 1 inhibitor, and an IFNγ inhibitor, wherein the CD103 inhibitor is an anti-CD103 antibody, selected from the group consisting of PE anti-human CD103 antibody derived from clone Ber-ACT8, mouse anti-human CD103 monoclonal antibody (mAb) derived from clone 2G5.1, humanized antibody of 2G5.1, OX-62, humanized antibody of OX-62, anti-mouse CD103 mAb derived from clone 2E7, humanized antibody of 2E7, and paxilin; the perforin 1 inhibitor is selected from the group consisting of diarylthiophene and GSK2126458; and the IFNγ inhibitor is selected from the group consisting of mesopram and locagramide.

Provided herein are compositions and formulations for alleviating problems associated with glaucomatous neurodegeneration and eye-related conditions, including administration of trapoxin (eye drops or SR) or MMP-based therapeutic modalities. Administration of trapoxin leads to elimination of the disease rate-limiting underlying cause associated with loss of neural lineage cells in glaucoma and related conditions.

The invention relates to the development of an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential to be used in the treatment of Alzheimer's and certain neurodegenerative disorders.

This disclosure provides (i) a benzo[c][1,2,5]thiadiazolyl-based target ligand that can bind to toxic peptides and / or protein aggregates in brain tissue (e.g., α-synuclein fibrils, amyloid plaques, and / or tau tangles) for degradation; (ii) a ubiquitin ligase mobilizing ligand; and (iii) a proteolytically targeted chimera containing a linker between (i) and (ii). These proteolytically targeted chimeras are useful for treating neurodegenerative disorders such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia.

This disclosure provides, for example, benzo[c][1,2,5]thiadiazole compounds and methods for using these compounds, for example, to treat neurodegenerative diseases such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia. This disclosure also provides the use of radioactive isotopes, for example... 11 C 18 F or 123 / 125 I. Methods for using radiolabeled benzo[c][1,2,5]thiadiazole compounds and the use of said radiolabeled compounds as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) brain imaging agents for the diagnosis of neurodegenerative diseases and / or for monitoring the treatment of neurodegenerative diseases.

The invention relates to gene therapy, and more specifically, to AAV gene therapy vectors containing a novel chimeric deoxyribonuclease (DNase) protein transgene and methods of treating ailments such as cancer and neurodegeneration.

The invention relates to a method for determining neurodegeneration of the brain by reading bioelectrical brain data. Brain signals are obtained. The obtained signals are digitized, unless already digitized. A digitized brain signal from each sensor is converted into a topological space object in the form of a piecewise linear curve of the trace of each digitized signal from each corresponding sensor. The rank of the curves is calculated as the maximum number of eigenvalues of the scattering matrix of a curve such that the other eigenvalues can be neglected. The number of active sources of each obtained brain signal is determined according to the rank of the corresponding curve, wherein if the number of such sources for at least one brain signal is less than a given number, this indicates neurodegeneration. The invention makes it possible to increase the speed of determining neurodegeneration and assessing the extent thereof by measuring brain signal complexity, while also maintaining a high level of accuracy.

A method for inducing an immune response against tau protein in subjects with neurodegenerative diseases, disorders, or conditions (e.g., Alzheimer's disease) is described. The method comprises administering a liposome-initiating composition containing a tau peptide (preferably phosphorylated tau peptide) and a conjugate-enhancing composition containing a tau peptide (preferably phosphorylated tau peptide) conjugated to an immunogenic carrier.

The problem to be solved by the present invention is to provide a medicament which, although it is a non-ergot dopamine agonist (DA), reduces the risk of drowsiness side effects and exhibits excellent therapeutic effects on neurodegenerative diseases such as Parkinson's disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmaceutically acceptable salt thereof. The pharmaceutical composition is characterized by oral administration at a daily dose of 0.25 mg to 2 mg in terms of the free form.

The invention relates to the development of an active agent increasing the activity of a-carbonic anhydrase (hCA) enzymes, having the potential to be used in the treatment of Alzheimer's and certain neurodegenerative disorders.

The invention relates to the development of an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential to be used in the treatment of Alzheimer's and certain neurodegenerative disorders.

Disclosed is a tricyclic pyrimidinone compound of Formula (I) or a pharmaceutically acceptable salt thereof, which is a novel Lp-PLA2 inhibitor useful in treating neurodegeneration-related diseases such as Alzheimer's disease (AD), glaucoma and age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis.

This application relates to a reagent and method for detecting neurodegenerative markers. The reagent comprises an oxygen-generating agent, a catalyst, and an immunoassay reagent capable of specifically binding to the target neurodegenerative marker in the sample. The oxygen-generating agent reacts under the action of the catalyst to generate oxygen, which increases the oxygen content in the reaction system. The immunoassay reagent utilizes reactive oxygen species in the reaction solution to generate a light signal, and the target molecule is selected from neurodegenerative markers. The method provided in this application can increase the light signal value even at low concentrations of neurodegenerative markers, thus improving the detection capability of neurodegenerative markers.

The present invention relates to novel carboxamide compounds of Formula-I, which act as potent activators of Exchange Protein Activated by cAMP 2 (EPAC2). The invention further provides a sustainable, one-pot process for the preparation of these EPAC2-activating compounds of Formula-I. Accordingly, the compounds are useful in the treatment and management of EPAC2-associated therapeutic conditions including neurological disorders, synaptic dysfunction, cognitive impairment, and neurodegeneration, as well as disorders linked to impaired cAMP-mediated neuronal signalling.